



Patient ID SA00127391	Patient Name SAMPLEREPORT, TB1LN	Birth Date 1977-02-01	Gender F	Age 43
Order Number SA00127391	Client Order Number SA00127391	Ordering Physician CLIENT,CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 05 Mar 2020 07:00		

Susceptibility, Mtb Complex, 1 Line

MCR



Abn

SOURCE: SPUTUM, INDUCED

SUSCEPTIBILITY, MTB COMPLEX, 1 LINE

FINAL

MYCOBACTERIUM TUBERCULOSIS COMPLEX

Organism identified by client.

Consult with a Pulmonary or Infectious Disease specialist in TB control for appropriate therapeutic regimen.

First line agents tested by broth dilution using critical concentrations and CLSI interpretive criteria.

Organism: MYCOBACTERIUM TUBERCULOSIS COMPLEX

Antibiotic	MIC (mcg/mL)	Interpretation
Ethambutol, Low	5	S
Ethambutol, High	8	S
Isoniazid, Low	0.1	S
Isoniazid, High	0.4	S
Rifampin	1	R

Ethambutol, Low: Value listed is the critical concentration rather than MIC.

Ethambutol, High: Value listed is the critical concentration rather than MIC.

Isoniazid, Low: Value listed is the critical concentration rather than MIC.

Isoniazid, High: Value listed is the critical concentration rather than MIC.

Rifampin: Value listed is the critical concentration rather than MIC.

S=SUSCEPTIBLE I=INTERMEDIATE R=RESISTANT
NS=NONSUSCEPTIBLE SDD=SUSCEPTIBLE DOSE
DEPENDENT

Received: 05 Mar 2020 10:24

Reported: 05 Mar 2020 10:26

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292

Patient ID SA00127391	Patient Name SAMPLEREPORT, TB1LN	Birth Date 1977-02-01	Gender F	Age 43
Order Number SA00127391	Client Order Number SA00127391	Ordering Physician CLIENT,CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 05 Mar 2020 07:00		

Susceptibility, Mtb Complex, 2 Line
1 MCR

Abn
SOURCE: SPUTUM, INDUCED
SUSCEPTIBILITY, MTB COMPLEX, 2 LINE
FINAL
MYCOBACTERIUM TUBERCULOSIS COMPLEX

Second line agents tested by microbroth dilution with the MIC reported using laboratory developed interpretive criteria.

Organism: MYCOBACTERIUM TUBERCULOSIS COMPLEX		
Antibiotic	MIC (mcg/mL)	Interpretation
Amikacin	0.12	S
Cycloserine	2	S
Ethionamide	0.3	S
Kanamycin	0.5	
Moxifloxacin	0.06	S
Ofloxacin	0.25	S
p-Aminosalicylic acid	0.5	S
Rifabutin	0.12	S
Streptomycin	0.25	S

S=SUSCEPTIBLE I=INTERMEDIATE R=RESISTANT
NS=NONSUSCEPTIBLE SDD=SUSCEPTIBLE DOSE
DEPENDENT

Received: 05 Mar 2020 10:24

Reported: 05 Mar 2020 10:29

Laboratory Notes

- 1** This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292

Report Status: Final

Printed 10 Mar 2020

Received and reported dates and times are reported in US Central Time.

Page 2 of 2